On Announcement of All Oral MDR TB regimen by Indian Government

26th Sep 2019, New Delhi

On 25 September Wednesday, at the event- TB Harega Desh Jitega organised in New Delhi, the Central TB programme announced the rolling out an all oral Multi Drug Resistant TB regimen across the country starting with four states, based on one of the two new drugs – Bedaquiline or Delamanid – replacing injectable in the treatment regimen.

While the announcement is a welcome step from the Indian government, in a context like India with high prevalence of fluoroquinolones resistance, many DR-TB patients would require both Bedaquilin and Delamanid in the treatment regimen. Without such access, all oral regimen for Pre-XDR and XDR patients will not become a reality.

The issue has already been raised by Indian civil society including TB survivors and activists by a letter in Dec 2018, demanding scale-up for Bedaquilin and Delamanid. The letter can be read here.

This entry was posted in Access to Medecines, Drugs, Multi-Drug Resistant Bacteria. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s